In MS patients, treatment with IFN-β leads to significant acute elevations in plasma or serum L-KYN levels and K/T ratio compared to baseline measurements, consistent with the induction of IDO in response to IFN-β (Amirkhani et al., 2005; Durastanti et al., 2011). Here, IFNB1 is linked to myeloid sarcoma.